Changing the Brain State of ADHD with a Pro Dopamine Regulator (KB220Z): A message of Hope



Austin, Texas; June 22, 2016: Attention-Deficit Hyperactivity Disorder (ADHD) is the leading psychiatric disorder which affects 6-10% of the American population of children. Unfortunately this inheritable condition continues through adulthood. The condition over the many years around the globe has been reviewed extensively in the peer-reviewed literature. The primary treatment of this condition is the utilization of Psychostimulants (e.g. Adderall, Ritalin) promoted in children. There has been some controversy as to the benefits vs the risk in terms of future drug seeking behaviors. While many have suggested that without such treatment individuals will indeed be at high risk for all Reward Deficiency addictive behaviors, others have suggested that stimulants increase drug seeking behaviors and their use has been questioned. 


It is now clear that one cause of this known genetic and or epigenetic induced phenomenon is a deficient dopaminergic function in the brain reward circuitry and resting state in ADHD patients, as reported by Dr. Rajendra D. Badgaiyan in a sophisticated neuroimaging study published in PLOS One. Understanding this dopamine deficiency based on many reports in the literature, Kenneth Blum, PhD, the product inventor,  along with Dr. Badgaiyan and others decided to test a novel, natural Pro-Dopamine Regulator known as KB220z (Synaptamine™-Liquid Nano) in a highly functional 72 year old physician diagnosed with ADHD, Inattention-type. The test used a sophisticated EEG analysis program known as Low-Resolution Electromagnetic Tomography (LORETA).


In a newly published study by Steinberg and associates, one hour after consumption of KB220z, compared to baseline imaging,  the results, averaged across Eyes Closed, Eyes Open, and Working Memory conditions, revealed increased electrical activity in the theta, alpha, and low beta frequencies while decreasing high beta electrical activity in areas of the brain involved with attention and memory. The LORETA software is being used by thousands of clinicians to help access and even treat ADHD across the United States. One of the authors Joel  Lubar, PhD an expert in the field of LORETA Technology and Neurofeedback, excited about the results stated- “Showing these interesting results even in only one  ADHD patient seems quite important and if this work can be confirmed in a much larger cohort of ADHD patients , especially children, it may represent a new treatment approach for ADHD”.



The lead author Bruce Steinberg, PhD is a Professor of Psychology at Curry College. He is in charge of the  Psychology Lab and has utilized the LORETA technique in research with students  with ADHD. Curry College is especially suitable for this study because of the college’s long-term commitment to the education of students with learning variations, including ADHD. Dr. Steinberg stated that while he was skeptical at first the findings obtained with just one dose of KB220Z were not only striking but selective and aligned with what one would expect in terms of neurobiological mechanisms that would be beneficial to an ADHD patient. Steinberg enthusiastically suggested “ If this finding can be consistently shown with a number of other ADHD patients, we just might have found a treatment, but not a cure, that seems to be acting on brain regions linked  to low dopaminergic function, increasing working memory , providing a message of hope for individuals afflicted with ADHD. “           


According the authors of the paper published in the Journal of Open Clinical Medicine & Case Reports These scores following administration of KB220Z are consistent with other human and animal neuroimaging studies that demonstrated increased resting state functional connectivity and connectivity volumes in reward circuitry in not only ADHD but even abstinent heroin and psychostimulant abusers.


 For more info


For More Information Please Contact:


Omni Publicity


Joe Ullrich





CREDENTIALS: Kenneth Blum, B.Sc. (Pharmacy), M.Sc., Ph.D. & DHL; received his Ph.D. in Neuropharmacology from New York Medical College and graduated from Columbia University and New Jersey College of Medicine. He also received a doctor of humane letters from Saint Martin’s University Lacey, WA. He has published more than 550 abstracts; peer-reviewed articles and 14-books. Dr. Blum has been the recipient of many NIH grants and numerous awards including the prestigious Life-Time Achievement in Addiction Medicine from The Holistic Institute of Addiction Studies and The Presidential Award for Scientific Excellence from National Council of Alcohol & Drug Abuse Councilors. Blum is the CO and Editor in Chief of “Addiction Genetics.”  Currently, Dr. Blum is serving as Editor-In-Chief of “Journal of Reward Deficiency Syndrome” and co-Editor-In-Chief of “Journal of Neuroimaging in Psychiatry and Neurology” and is on 7 prestigious journal editorial boards. Prof. Blum is also a founder President of USG and founder President of USG Editors Association (USGEA). Dr. Blum is the recipient of Julius Axelrod (Nobel Laureate) Distinguished Speaker Award



Powered by WPeMatico